Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women.

Fayet-Mello A, Buclin T, Guignard N, Cruchon S, Cavassini M, Grawe C, Gremlich E, Popp KA, Schmid F, Eap CB, Telenti A, Biollaz J, Decosterd LA, Martinez de Tejada B; Swiss HIV Cohort Study.; Mother & Child HIV Cohort Study..

Antivir Ther. 2013;18(2):171-82. doi: 10.3851/IMP2328. Epub 2012 Aug 22.

PMID:
22914504
2.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
3.

Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.

Calza L, Manfredi R, Trapani F, Salvadori C, Colangeli V, Borderi M, Grossi G, Motta R, Viale P.

Scand J Infect Dis. 2012 May;44(5):381-7. doi: 10.3109/00365548.2011.642306. Epub 2012 Jan 21.

PMID:
22263609
4.

Reduced lopinavir exposure during pregnancy.

Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS.

AIDS. 2006 Oct 3;20(15):1931-9.

PMID:
16988514
5.

Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.

Else LJ, Douglas M, Dickinson L, Back DJ, Khoo SH, Taylor GP.

Antimicrob Agents Chemother. 2012 Feb;56(2):816-24. doi: 10.1128/AAC.05186-11. Epub 2011 Nov 21.

6.

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.

Zorrilla CD, Wright R, Osiyemi OO, Yasin S, Baugh B, Brown K, Coate B, Verboven P, Mrus J, Falcon R, Kakuda TN.

HIV Med. 2014 Jan;15(1):50-6. doi: 10.1111/hiv.12047. Epub 2013 Jun 3.

7.

Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines.

Patterson KB, Dumond JB, Prince HA, Jenkins AJ, Scarsi KK, Wang R, Malone S, Hudgens MG, Kashuba AD.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):51-8. doi: 10.1097/QAI.0b013e31827fd47e.

8.

Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment.

Fauchet F, Treluyer JM, Illamola SM, Pressiat C, Lui G, Valade E, Mandelbrot L, Lechedanec J, Delmas S, Blanche S, Warszawski J, Urien S, Tubiana R, Hirt D.

Antimicrob Agents Chemother. 2015 Sep;59(9):5727-35. doi: 10.1128/AAC.00863-15. Epub 2015 Jul 6.

9.

No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects.

Salem AH, Jones AK, Santini-Oliveira M, Taylor GP, Patterson KB, Nilius AM, Klein CE.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):400-8. doi: 10.1128/AAC.01197-15.

10.

Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.

Sturt AS, Dokubo EK, Sint TT.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008440. doi: 10.1002/14651858.CD008440. Review.

PMID:
20238370
11.

Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy.

Cressey TR, Urien S, Capparelli EV, Best BM, Buranabanjasatean S, Limtrakul A, Rawangban B, Sabsanong P, Treluyer JM, Jourdain G, Stek A, Lallemant M, Mirochnick M.

J Antimicrob Chemother. 2015 Jan;70(1):217-24. doi: 10.1093/jac/dku367. Epub 2014 Sep 25.

12.

Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding.

Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlebois E, Ruel TD, Huang Y, Clark T, Ades V, Natureeba P, Luwedde FA, Achan J, Kamya MR, Havlir DV, Cohan D; Prevention of Malaria and HIV disease in Tororo (PROMOTE) study..

J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):578-84. doi: 10.1097/QAI.0b013e31829c48ad.

13.

Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure.

Ofotokun I, Lennox JL, Eaton ME, Ritchie JC, Easley KA, Masalovich SE, Long MC, Acosta EP.

J Clin Pharmacol. 2011 Nov;51(11):1539-48. doi: 10.1177/0091270010385118. Epub 2011 Jan 5.

14.

Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.

van der Lee M, Verweel G, de Groot R, Burger D.

Antivir Ther. 2006;11(4):439-45.

PMID:
16856617
15.

Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment.

Bouillon-Pichault M, Jullien V, Azria E, Pannier E, Firtion G, Krivine A, Compagnucci A, Taulera O, Finkielsztejn L, Chhun S, Pons G, Launay O, Treluyer JM.

J Antimicrob Chemother. 2009 Jun;63(6):1223-32. doi: 10.1093/jac/dkp123. Epub 2009 Apr 22.

PMID:
19389715
16.

Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.

Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, Ruggeri M, Suter F.

AIDS. 2007 Nov 30;21(18):2409-15.

PMID:
18025877
17.

Pharmacokinetics of tenofovir during pregnancy and postpartum.

Best BM, Burchett S, Li H, Stek A, Hu C, Wang J, Hawkins E, Byroads M, Watts DH, Smith E, Fletcher CV, Capparelli EV, Mirochnick M; International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) P1026s Team..

HIV Med. 2015 Sep;16(8):502-11. doi: 10.1111/hiv.12252. Epub 2015 May 11.

18.

Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients.

Ramautarsing RA, van der Lugt J, Gorowara M, Sophonphan J, Ananworanich J, Lange JM, Burger DM, Phanuphak P, Ruxthungtham K, Avihingsanon A.

Antivir Ther. 2013;18(2):249-52. doi: 10.3851/IMP2324. Epub 2012 Aug 23.

PMID:
22908131
19.

Pharmacokinetics of antiretrovirals in pregnant women.

Mirochnick M, Capparelli E.

Clin Pharmacokinet. 2004;43(15):1071-87. Review.

PMID:
15568888
20.

Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.

Yilmaz A, Ståhle L, Hagberg L, Svennerholm B, Fuchs D, Gisslén M.

Scand J Infect Dis. 2004;36(11-12):823-8.

PMID:
15764168

Supplemental Content

Support Center